Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Dar© Bioscience and Theramex Announce Co-Development for Contraceptive Implant
Details : Under the licensing agreement, Dare will develop Casea S (etonogestrel), a potential first-in-category contraceptive candidate for women.
Product Name : Casea S
Product Type : Hormone
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Daré Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 15, 2025
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : University of Saskatchewan
Deal Size : Inapplicable
Deal Type : Inapplicable
Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : University of Saskatchewan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Merck Announces Completion of Organon & Co. Spinoff
Details : Organon will pursue sustainable growth in Women’s Health led by patent-protected Nexplanon (etonogestrel implant) franchise and fueled by its leading contraceptive and fertility businesses. It expects to establish a leading position in Biosimilars focu...
Product Name : Nexplanon
Product Type : Hormone
Upfront Cash : Undisclosed
March 06, 2021
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Organon
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Details : Organon’s commercial strategy will center around Nexplanon (etonogestrel implant), its long-active reversible contraceptive, that delivered approximately $1.6 billion in global sales in 2020.
Product Name : Nexplanon
Product Type : Hormone
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Merck & Co | Wits Reproductive Health and HIV Institute | University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Merck & Co | Wits Reproductive Health and HIV Institute | University of Washington
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 12, 2020
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Merck & Co | University of Colorado, Denver | University of Pennsylvania
Deal Size : Inapplicable
Deal Type : Inapplicable
Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 09, 2020
Lead Product(s) : Etonogestrel,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Merck & Co | University of Colorado, Denver | University of Pennsylvania
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement
Mithra to Commercialize Myring In France, Poland And UK
Details : Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets.
Product Name : Myring
Product Type : Hormone
Upfront Cash : Undisclosed
June 07, 2020
Lead Product(s) : Etonogestrel,Ethinyl Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Zentiva
Deal Size : $2.2 million
Deal Type : Agreement